Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You lose! 2.31 or 2.33 after hours.
Thanks CHM_760, More exposure! Love it and thanks again.
Its nice to see some of the day traders starting to see sense on this one and go LONG (more than a year, I hope ;) ).
Yes, I have heard the same thing for 19 months cravity! From day one when I bought in at 0.54 and I have bought from 0.49 up to 2.22! So if you think advertising how good a company is and then the share price rises and rises, and I am "pumping" probably the BEST IN CLASS bio stock, GUILTY as CHARGED!
LOLOL, there are so many more who think that $20 and much much more stock_risk! I personally believe we see $100 PPS within 4 years! And I may add, NO CEILING to where it will end!
Nothings Changed! Nothings Diluted and NOTHINGS NEW!
READ IT AGAIN!
BLUE BELL, Pa., Feb. 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
If you still can't understand what is written, then you shouldn't be investing/shorting/day trading in stocks and shares IMHO!
I could start ranting and raving at those who think we will retract to 2.80's but I won't! Instead I will think about those people while the share price rises and rises! I was going to remind others that the HPV results could be released as early as the 1st April and as late as the 30th of September! Why? Because although Inovio will no doubt get the results peer reviewed, it doesn't mean they cannot put out a PR news item saying the results were good/very good or excellent! OH! God damn I said it! Have a great day :)Inovian LONGS
Oh! Utube: "The only way is UP" By Yazz
Are you trying to get me banned again? lolol. Visit www.inovio.com
I'm sorry that you consider my posts as battles pistolp. I was just replying to someone else's opinion with my own opinion on the same subject. That is no battle unless you choose to see it that way. If someone writes a post recommending something they believe I feel obliged to give my opinion on what I believe. Should we get 100's of posters suggesting that INO's SP will decline back to below $3 what would the consequences be? Well IMO sure the price would drop below $3 because many people believe everything they read and get scared into selling. So, do the people who write posts about the price dropping back have an ulterior motive? Just may be they do! I'm only here to keep investors focused on what is and not what might be! Otherwise I will write posts saying INO will be $5 on Monday! Which they won't, not until Tuesday LOLOL Good day pistol!
50 different stocks? So tell me someconcern how do you manage to do you're research when invested in 50 different stocks? IMHO this makes you sound like you dabble in many but master of none! I have copious amounts of research time on Inovio and I mean copious amounts of time! First bought back in August 2012 @ 0.54 and continued buying up to 2.22 PPS. I would of continued buying but all my spare money and I mean ALL my spare money has been put into INO until now where I own 25350 shares. My AVG is 0.98 approx so you can work out the gains made for yourself. I would personally prefer to know the in's and out's of a single great company than invest in 10,30 or 50 different companies and master none of them! Yes, I have mastered INO! Good luck to you and those who do not have the patience to research deeper than just the surface before they invest. Lets be honest someconcern, how would anyone be able to do deep research in 50 different companies unless you are simply relying other people's words and info? GLTA LONGS
Don't make another mistake someconcern! BUY & HOLD!
I love all the "I sold some" and nobody ever lost money selling with a profit" chat! If I sold at $3 and now they are $3.17, then I have lost the difference between the 2 figures, correct? And if we finish higher than $3.17 I would feel I have lost more! You can sell at any time also! I will be holding LONG and I mean LONG! lolol
It takes time for people to find INO, but when they do, they can't help but BUY! Then, once they buy one time they are hooked and will continue to BUY at every chance they get! This has happened to the best of the best investors and the one's who think they are shrewder than most out there! I can't get my head around the thought that I have been buying since 0.49 back in August 2012 and today we are on the verge of hitting and passing the all time high of $3.03 again! Its a great feeling being invested in a company were there CEO is 99.9% invested himself! Things couldn't feel better for me!
I'm betting against that! And so far I'm up more than you so my method on this stock works! The higher the share price the less you will have to play with! Don't get caught on the OUTSIDE!
Well I have bought from 0.49 to 2.22, 25350 shares with an average of less than a $1! So I guess that make my profit higher than yours and I still have my shares and I haven't paid 1 cent in tax! Now you may say that you haven't make a cent until sold, which is true, but I can sell at any time I choose! So My investment was £14200.00 = $23400. Today my dollar amount is $72,233.50 which shows its worth up $48,833.50. I like being LONG and NO TAX!
From the Motley Fool today:
These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common
By Sean Williams | More Articles
February 18, 2014 | Comments (0)
Change typically doesn't hit the health care industry all at once, but in practically a blink of an eye, cancer immunotherapies -- training the body's immune system to recognize and attack cancer -- are all the rage.
We can certainly point to the American Society of Clinical Oncology meeting in 2013 as the reason this treatment pathway took center stage, with Bristol-Myers Squibb's nivolumab and Merck's lambrolizumab, which both treat advanced types of melanoma, stealing the show. These two experimental therapies are part of an exciting class of PD-1 inhibitors which, in really early-stage studies, delivered stunning overall response rates (ORR). A phase 1 study that combined nivolumab with FDA-approved Yervoy delivered an ORR of 53%, while the optimal dosage of lambrolizumab produced an ORR of 52%.
Yet, the truth of the matter is that there are a number of advancing cancer immunotherapy studies currently under way from the likes of Dendreon (NASDAQ: DNDN ) , Galena Biopharma (NASDAQ: GALE ) , NewLink Genetics (NASDAQ: NLNK ) , Peregrine Pharmaceuticals (NASDAQ: PPHM ) , and Inovio Pharmaceuticals (NYSEMKT: INO ) as well. In other words, cancer immunotherapy studies aren't exclusive to Bristol and Merck.
Macrophages fusing with cancer cell. Source: Dr. Raowf Guirguis, Wikimedia Commons.
These companies share one common bond
However, these five immunotherapy-focused companies above do share a bond that extends beyond their research. This bond in question is that they're all relatively small ($1 billion in market value or less) all things considered, and that a majority of their valuation is based on the future success of one or two therapies within their respective pipelines.
Let's have a quick look at each pipeline so you can get a better idea of how much "hope" is really baked into each of their valuations. Keep in mind that my intent is not to pass judgment in a good or bad sense on any of these five immunotherapy-focused companies, but to instead highlight which one or two immunotherapy drug hopefuls could make or break these companies.
Dendreon
Dendreon is really the only established biopharma of the group, with its metastatic prostate cancer immunotherapy Provenge being approved by the FDA in April 2010. Dendreon's therapy works by collecting some of a patients' immune cells (a process known as leukapheresis), exposing those cells to a signature protein from the targeted cancer, and then reinjecting those immune cells so they can target prostate cancer cells. In trials, Provenge was shown to have improved median overall survival by a tad over four months.
Unfortunately for Dendreon, competition in treating metastatic prostate cancer has been increasing at a ferocious pace, and Dendreon didn't exactly handle its product launch very well. Peak sales expectations for its immunotherapy vaccine have fallen from $4.3 billion a few years ago to roughly 10% of that total today, even with its recent European approval. If Dendreon is unable to cut its costs with its second restructuring in as many years, the company's share price may have further downside.
Galena Biopharma
Galena might be the poster child for unbridled hopes and dreams in the biotech sector, with its share price both more than quadrupling and losing more than half of its value in just the past couple of months. There are a number of factors at work here for this volatility, but I'd surmise that the bulk of Galena's hope is built into the success or failure of its cancer immunotherapy NeuVax.
NeuVax is targeted at HER2-negative breast cancer patients (the predominant type of breast cancer) as an adjuvant therapy to help them maintain their disease-free status. Without getting too technical, NeuVax stimulates specific CD8+ cytotoxic T-lymphocytes causing them to recognize and destroy HER2-expressing cancer cells. In the final results from its phase 2 trial, Galena reports that at the 60-month mark, only 5.6% of NeuVax intent-to-treat subgroup of patients had a relapse, while 25.9% of patients in the control arm had a cancer reoccurrence. Overall, this represents a recurrence reduction of 78.4% in the target population and was more than enough to justify its ongoing phase 3 studies of the vaccine. It will still be a while before we have the results from Galena's phase 3 study, but NeuVax certainly has make-or-break potential for Galena.
NewLink Genetics
Unlike Dendreon and Galena, NewLink Genetics really has two products in its HyperAcute immunotherapy platform working side by side to give the company its current $1 billion valuation -- algenpantucel-L in two separate late-stage pancreatic cancer studies and tergenpumatucel-L in relapsed or refractory non-small cell lung cancer (NSCLC).
Source: Novartis.
NewLink's immunotherapy treatments work by modifying existing cancer cell lines to express alpha-gal, a carbohydrate that the human body has a natural immunity to. Once in the body, alpha-gals train the body to recognize these cancer cells and to seek out and destroy them. In early June, NewLink released phase 2 data on tergenpumatucel-L for NSCLC, noting that it delivered median overall survival of 11.3 months and long-term stable disease in eight of 28 evaluable patients.
Just days later, NewLink reported phase 2 data from a resected pancreatic cancer study involving algenpantucel-L, which demonstrated disease-free survival in 62% of patients after one year. The data also showed a median overall survival of 42 months in patients with elevated levels of anti-mesothelin antibodies, which was more than double the median overall survival of patients without elevated levels. NewLink's treatments are therefore very specialized, and based on its $1 billion valuation, hopes for its success run high.
Peregrine Pharmaceuticals
With the exception of Cotara and PGN650, an early-stage tumor imaging agent, Peregrine's entire valuation is based on immunotherapy agent bavituximab which is being tested in both first- and second-line non-small cell lung cancer, liver cancer, and HER2-negative breast cancer, to name a few studies.
Peregrine's bavituximab is unique in that it's a phosphatidylserine (PS)-targeting monoclonal antibody. In easier to understand terms, PS is an immunosuppressive molecule typically found inside healthy cells, but in tumor cells, it's located on the outside of the cell, providing immune response protection. Bavituximab aims to block this immunosuppressive response and allow the body's immune system to recognize and destroy these cancer cells.
No trial is currently more important to Peregrine than its second-line NSCLC study, which is currently in phase 3 trials. Although its phase 2 results were far more complicated than they should have been, the end result was a better-than-doubling in median overall survival to 12.1 months from 5.6 months in the control arm. Bavituximab also delivered a 40% increase in progression-free survival, to 4.2 months from 3.0 months. Without question, this phase 3 study will go a long way to proving or disproving the viability of Peregrine's immunotherapy.
Inovio Pharmaceuticals
Inovio Pharmaceuticals might be the one exception to the rule, here, since it has four cancer-focused immunotherapies in development in addition to a number of clinical and preclinical HIV and hepatitis-focused vaccines.
Inovio's claim to fame in this space is its SynCon vaccine platform, which utilizes synthetic DNA to target multiple disease antigens and break down whatever immune resistances may exist. The company's SynCon vaccines have thus far been developed to treat cervical dysplasia/cancer, as well as cancers that express hTERT such as breast, lung, and pancreatic cancer.
Despite having a number of existing trials, only one of Inovio's in-house studies has advanced beyond phase 1. However, this vaccine, VGX-3100, demonstrated incredibly promising early-stage immune responses to antigens from the human papillomavirus infection. Early data showed that VGX-3100 was effective at destroying precancerous cervical dysplasias that had been transformed by HPV, meaning it could have early- and later-stage success in treating cervical cancer.
Nice post Aball1979! And I agree totally! Why limit yourself to one, two or three MB's when you can join ALL! No brainer really IMO! Thanks for the post!
So Mr Moderator, Hugo the fool can post lies and misleading advice on this INO MB and yet he is allowed to carry on posting? When I posted to some that I believed to be over negative on INO I got banned, not once not twice but 3 times! I also requested to be allowed back as so to be able to post more than just one time in a day, yet to hear from any moderator and when I tried, nothing happens! It seems to me that I can lie on this MB and all is fine because you say its my opinion and all opinions are welcome! Ummmmmmmmm JUST SAYING!
Dear Friends, The Facebook page is not about taking members away from any other message board. Its just another message board with like minded people who can discuss in depth ideas and thoughts pertaining to Inovio Pharma. The negatives if there are any as well as the positives! This FB page takes away the stupid nonsensical noise created by some in order to make the conversation weak and meaningless as well as forcing the factual posts to the bottom. I will be posting on all my normal MB's but when I want to discuss something immediately, I will go to the FB page. There will no doubt be some who are unwilling to join for whatever reason, but today 2014! Get with it folks! Even this message board is on the internet for all to read, so if you think you are in fact hiding away, you are not! https://www.facebook.com/groups/Inovio/ Join if you like but there is nobody forcing you to! So stop trying to run it down just because 1 or 2 people cannot keep up with the times! LOLOL. There are ways of keeping yourself private on the FB account! OR are some scared to put a face to their name? I doubt we will see hugo as he likes to be anonymous as do ALL the basher's! Constructive criticism is always welcomed! Have a great day ALL LONGS!
http://media.bloomberg.com/bb/avfile/vSADLphUrqOI.mp3
Dr Kim on Bloomberg radio yesterday.
Thanks to Chris Kalopsis from the Inovio Facebook Page!
Thanks plain_ole_pain, are you saying that Inovio Pharma are going to be HUGE? Are you saying that US investors of Inovio are on the right path to fortune? Are you confirming my belief in this ground breaking scientific time bomb waiting to explode? AND, the INSIDE buyers seem to know what they are buying! I guess it's a BIG yes to all! Cheers!
Thanks hlegweakreturns for you're great insightful post! As usual you have shown many investors which direction INO are heading, thanks again!
Agree everywhereman, personally I think the electroporation will work as usual but the drug ONCS use may not! Sure, we will have to wait and see. Even if the electroporation is sound but the vaccine may not work as per usual INO will feel the effects. And then again if both work, INO will feel the effect in a positive way. I also can't see Dr Kim selling for a poultry 2 billion when he believes that what he holds in his hands to be worth 30 billion in the not too distant future. There are those who would jump at the chance of getting $10 per share in a buyout, but I personally wouldn't! I'm in this for the long run and over $100 PPS. Onwards & UPwards Inovio!
Anyone know why VGX is MINUS 100% @ 0.00 on the yahoo finance?
I think norich123 was being sarcastic SABAI!
Good post, in simple terms, if in doubt, DO MORE RESEARCH! I have been invested for 16 months and accumulated over 25,000 shares from 0.49 upto 2.22 with an average of 0.98. I have seen all the games played on the YMB and have found out many snakes on there. I have been deleted over 20 times now and mostly because of basher's reporting me or using the thumbs down buttons (Possibly from cut & pastes also). My posts are never lies and always based on facts. I do find it incredible how the basher's are able to make false statements yet never get deleted. A good example is mmrich, he used to be a positive person when discussing INO and suddenly has turned negative. He must of sold up all his shares at a lower price expecting to buy back in at a lower price. As such he will post doom and gloom in the hope others will follow his advice and sell bringing the share price down. Down until he feels confident in buying again to make a quick profit, Rinse and repeat! I AM AN INVESTOR! NOT A TRADER! NEVER TRUST ANYONE, ESPECIALLY TRADERS AND SHORTS! Do your own research and when doubts pop up which they will because this company are achieving the unbelievable, DO MORE RESEARCH! This is the REAL DEAL IMHO, don't get mugged in the daylight!
I LOVE INOVIO and dislike the games others will play to rob the innocent investor! THIS IS THE REAL DEAL!
Shut up lol, I'm so eefing jealous everywhereman! I'm all spent up :(
Onwards & UPwards Inovio!
The Best-Performing Biotech Stocks Of The Past 52 Weeks
http://www.forbes.com/sites/matthewherper/2013/11/16/the-best-and-worst-performing-biotech-stocks-nov-8-to-nov-15/
I don't know where to begin really! 157,000 shares in one company that is UP over 300%! And you call this bad investing? Oh those with little faith! You stick to the charts and the genuine longs will stick to the fundamentals, we will see who profits at the end of the day! I WISH I HAD 157,000 SHARES OF INOVIO, yet you make a joke of someone who is well and truly UP BIG TIME on his investment! I get just a little sick of all the TA people who cannot see further than then end of a chart! Charts are JUST a indication, fundamentals are sound!If what I write isn't true, why have INO gone up in value? I can't see anywhere on the charts where it tells me it was going to go up over the last few days!
Has this been posted before?
http://www.frontiersin.org/Journal/10.3389/fimmu.2013.00354/abstract
If not, make sure you read this article! If it has, then read it again ;)
Great post ringo! Onwards and Upwards Inovio
Harvested in chicken eggs! So no they didn't steal INO's science.